Trial Profile

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INBRX 106 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Inhibrx

29 Jul 2026 Planned number of patients changed from 333 to 340.
29 Jul 2026 Planned End Date changed from 12 May 2027 to 1 Jul 2033.
29 Jul 2026 Planned primary completion date changed from 30 Oct 2026 to 1 Jul 2033.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com